Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Healthy males or females subjects~* Age 18 to 50 years (incl.)~* Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.)~* Signed and dated written informed consent prior to admission to the study~Exclusion criteria:~* Any finding in the medical examination (including blood pressure, pulse rate or ECG) deviating from normal and judged clinically relevant by the investigator.~* Systolic blood pressure (BP) less than 100 mmHg and more than 140 mmHg.~* Diastolic BP less than 60 mmHg and more than 90 mmHg.~* Pulse rate (PR) less than 50 bpm and more than 90 bpm.~* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance~* Any evidence of a concomitant disease judged clinically relevant by the investigator~* Positive QuantiFERON-TB Gold In-Tube

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 Cyclosporine + Faldaprevir (Type: EXPERIMENTAL): None
- 2 Tacrolimus + Faldaprevir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).